Kendahl L. Ott

This study identifies a shark-derived VNAR that binds a hidden epitope on FAP, revealing structural insights for multiepitope targeting strategies.

This study engineers single-domain antibodies to improve targeting of FAP, showing that valency and molecular weight affect tumor uptake and biodistribution.

This paper develops a shark-derived VNAR-based theranostic agent for MET-altered NSCLC, showing imaging and therapeutic efficacy in preclinical models.

This study presents crystal structures of VNARs targeting sTNF- with distinct epitopes, showing selective antagonism without inducing reverse signaling.

The paper develops FAP-targeted theranostics using VNARs from a shark antibody library, showing high affinity and efficacy in vitro and in vivo.